Ultragenyx Pharmaceutical Inc is a pioneering biopharmaceutical firm dedicated to advancing healthcare for those facing rare and ultra-rare genetic diseases globally. With a portfolio that includes Crysvita for X-linked hypophosphatemia, Mepsevii for Mucopolysaccharidosis VII, Dojolvi for long-chain fatty acid oxidation disorders, and Evkeeza for homozygous familial hypercholesterolemia, Ultragenyx is at the forefront of developing innovative treatments. Additionally, the company is exploring gene therapies and monoclonal antibodies for various genetic conditions, demonstrating its commitment to transforming patient lives through science. Founded in 2010 and based in Novato, California, Ultragenyx collaborates with leading healthcare and research institutions to fulfill its mission.